No annual revenue total was found in PDS Biotechnology Corporation's SEC filings.
PDS Biotechnology Corporation (PDSB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$27.8 million. As of Jun 30, 2026 it held $5.6 million in cash and investments and $41,172 in total debt.
Revenue
—
Net income (TTM)
$-33.67M
+8.0% vs year-ago TTM
Operating cash flow (TTM)
$-16.78M
+51.2% vs year-ago TTM
Free cash flow
$-27.75M
+20.8% vs prior year
EPS (TTM)
$-0.64
+29.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
55.82M
+23.0% vs prior year
Net cash
$5.56M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PDSB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1472091
- Former names
- Edge Therapeutics, Inc. (until Mar 18, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$31.5M | -$36.3M | -$43.0M | -$41.7M | -$21.4M |
| Net income | -$34.5M | -$37.6M | -$42.9M | -$40.9M | -$16.9M |
| Diluted EPS | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 |
| Operating cash flow | -$27.8M | -$35.0M | -$33.6M | -$25.7M | -$12.5M |
| Free cash flow | -$27.8M | -$35.1M | — | — | — |
| Total assets | $30.5M | $45.4M | $59.4M | $77.0M | $67.2M |
| Total liabilities | $21.2M | $26.4M | $33.3M | $33.0M | $4.0M |
| Stockholders' equity | $9.3M | $19.0M | $26.1M | $44.0M | $63.2M |
| Cash and investments | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M |
| Total debt | $61,853 | $122,972 | $178,767 | $452,054 | $490,354 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 20, 2026 | Oct 18, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change, Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 12, 2026 |
All 795 PDS Biotechnology Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.